Omalizumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Persistent Allergic Asthma
Conditions
Persistent Allergic Asthma
Trial Timeline
Sep 1, 2010 → Oct 1, 2013
NCT ID
NCT01202903About Omalizumab + Placebo
Omalizumab + Placebo is a phase 3 stage product being developed by Novartis for Persistent Allergic Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT01202903. Target conditions include Persistent Allergic Asthma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03369704 | Phase 3 | Completed |
| NCT03328897 | Phase 3 | Completed |
| NCT01723072 | Phase 3 | Completed |
| NCT01202903 | Phase 3 | Completed |
| NCT01007149 | Phase 3 | Completed |
| NCT00870584 | Approved | Completed |
| NCT00657891 | Approved | Completed |
| NCT00454051 | Approved | Completed |
| NCT01393340 | Phase 2 | Completed |
| NCT00123630 | Phase 2 | Completed |
Competing Products
20 competing products in Persistent Allergic Asthma